Want to make interactive content? It’s easy in Genially!
Get started free

Over 30 million people build interactive content in Genially.

Check out what others have designed:

LET’S GO TO LONDON!

Personalized

SLYCE DECK

Personalized

ENERGY KEY ACHIEVEMENTS

Personalized

CULTURAL HERITAGE AND ART KEY ACHIEVEMENTS

Personalized

ABOUT THE EEA GRANTS AND NORWAY

Personalized

DOWNFALLL OF ARAB RULE IN AL-ANDALUS

Personalized

HUMAN AND SOCIAL DEVELOPMENT KEY

Personalized

Discover more incredible creations here

Transcript

Examining X:BOT Data

Start

RCT (2017): IM Naltrexone (NtxO) vs. Buprenorphine-Naloxone (Bup-Nx)

Ntx n = 283, Bup-Nx n = 287​Ntx: high (89%) early return to use due to failed induction​Bup-Nx: More negative UDS, opioid-abstinent days​For those who completed induction: equal 24w relapse ​Similar rates of adverse events, overdose rates (excluding site reactions)​Re-analysis (2022): Ntx higher overdose rate during treatment phase​

X:BOT Data on Naltrexone

Next

X:BOT (Extended-Release Naltrexone versus Buprenorphine for Opioid Treatment)

Buprenorphine

No Buprenorphine

  • n = 197​
  • Associated with less 1-year re-arraignment, re-incarceration​
  • Lower recidivism​
  • hazard ratio (HR) = .71​
  • p= 0.001​

  • n = 287​
  • Associated with more re-arraignment, re-incarceration​
  • Higher recidivism​

Buprenorphine and Recidivism: JCOIN 2022​

“Findings support the growing movement in jails nationwide to offer buprenorphine and other agonist medications for opioid use disorder.”​

JCOIN (Justice Community Opioid Innovation Network)